Wen Bixin, Yao Jinling, Wang Shilong, Xu Binhao, Zhang Yuanjing, Wang Wen, Xu Qiaochu, Li Li, Liu Changhong, Huang Yaqing, Hanada Satoshi, Wang Min, Shi Yuhui, Zhang Zhenrong, Liang Chaoyang, Zhang Yajun, Chen Ying, Yang Yang, Ma Qianli
China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Wisdom Lake Academy of Pharmacy, Xi'an Jiaotong-Liverpool University, Suzhou, China.
J Thorac Dis. 2025 Apr 30;17(4):2594-2604. doi: 10.21037/jtd-2025-654. Epub 2025 Apr 22.
The analgesic efficacy of intercostal nerve block (ICNB) in adults undergoing thoracic surgery and the optimal extent of nerve block remain unclear. To evaluate the analgesic efficacy of ICNB and the optimal extent of nerve block in adults undergoing thoracoscopic surgery, we conducted a prospective cohort study of post-thoracoscopic pain.
We conducted a prospective observational cohort study to assess the postoperative pain intensity scores and other relevant factors associated with different ICNB techniques for pain management in thoracoscopic surgery in a tertiary hospital in Beijing, China. Postoperative pain management was categorized into three groups: the ICNB single-site injection (ICNB SI) group, in which the third to fifth intercostal nerves were blocked with 1 mL of 0.5% ropivacaine at each costal level; the ICNB incision-specific multi-site injection (ICNB ISMSI) group, in which the third to eighth intercostal nerves were blocked with 1 mL of 0.5% ropivacaine at each costal level; and the non-ICNB anesthesia group, which did not undergo any block.
Pain intensity scores (visual analog scale, VAS) in the ICNB SI group were significantly lower than those in the ICNB ISMSI group within 24 hours after surgery (4.9±2.4 6.2±2.0). Within 24 hours after surgery (day 0), no significant difference in pain intensity scores was observed between the ICNB ISMSI group and the non-ICNB group (6.2±2.0 6.3±2.1). Additionally, ICNB was effective in reducing pain following thoracoscopic surgery, with analgesic effects lasting up to 4 days postoperatively. Long-term follow-up showed lower incidence of chronic chest pain and better quality of life (QL-Index) in the ICNB groups compared to the non-ICNB group (QL-Index scores: 9.18±0.7 at 3 months in the ICNB group 8.67±0.5 in the non-ICNB group).
Thoracic incision-specific multi-site injections were not superior to single injections of ICNB in terms of post-thoracoscopic analgesia. The single-injection approach (ICNB SI) maintained analgesia for 4 days after thoracoscopic surgery, while the multisite injection (ICNB ISMSI) did not demonstrate this prolonged effect. Further research is needed to elucidate the exact mechanisms underlying these differential analgesic effects in clinical practice.
肋间神经阻滞(ICNB)在接受胸外科手术的成年人中的镇痛效果以及神经阻滞的最佳范围尚不清楚。为了评估ICNB在接受胸腔镜手术的成年人中的镇痛效果以及神经阻滞的最佳范围,我们对胸腔镜术后疼痛进行了一项前瞻性队列研究。
我们进行了一项前瞻性观察性队列研究,以评估中国北京一家三级医院中不同ICNB技术用于胸腔镜手术疼痛管理的术后疼痛强度评分及其他相关因素。术后疼痛管理分为三组:ICNB单点注射(ICNB SI)组,在每个肋间隙水平用1 mL 0.5%罗哌卡因阻滞第三至第五肋间神经;ICNB切口特异性多点注射(ICNB ISMSI)组,在每个肋间隙水平用1 mL 0.5%罗哌卡因阻滞第三至第八肋间神经;非ICNB麻醉组,未进行任何阻滞。
ICNB SI组术后24小时内的疼痛强度评分(视觉模拟量表,VAS)显著低于ICNB ISMSI组(4.9±2.4对6.2±2.0)。术后24小时内(第0天),ICNB ISMSI组与非ICNB组之间的疼痛强度评分无显著差异(6.2±2.0对6.3±2.1)。此外,ICNB在减轻胸腔镜术后疼痛方面有效,镇痛效果可持续至术后4天。长期随访显示,与非ICNB组相比,ICNB组慢性胸痛的发生率较低,生活质量(QL-Index)较好(QL-Index评分:ICNB组3个月时为9.18±0.7,非ICNB组为8.67±0.5)。
在胸腔镜术后镇痛方面,胸腔切口特异性多点注射并不优于ICNB单点注射。单次注射方法(ICNB SI)在胸腔镜手术后维持镇痛4天,而多点注射(ICNB ISMSI)未显示出这种延长效果。需要进一步研究以阐明临床实践中这些不同镇痛效果的确切机制。